Amedica's stock price rose 23.08 percent last week, although the bid price remains under $1, which could be problematic for the company to remain listed, according to a Winston View report.
The stock is up 14.29 percent over the past four weeks. The counter outperformed the S&P 500 by 22.3 percent with out-performance increases to 11.12 percent. According to the Feb. 22 report, the company "did not lose steam" from an intraday rally and hit a high of +0.8794.
The increases are crucial for the company, which received a letter from Nasdaq on Feb. 20 noting the company's stock hasn't been above $1 for 30 consecutive days, which is a requirement for the Nasdaq Listing.
Amedica has until Aug. 18 to get bid price above $1 for 10 or more consecutive days. The company's 52-week low is 0.5501. Last December, the company announced restructuring for a better focus on core competencies and Sonny Bal, MD, recently took over as CEO.